Toshihiko Ishii
Shimotogari, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Preclinical Ocular Pharmacokinetics and Efficacy of Novel Tivozanib Eye Drops for Neovascular Age-Related Macular Degeneration.
Journal: Investigative ophthalmology & visual science
Published: July 27, 2026
A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model.
Journal: Cancer immunology, immunotherapy : CII
Published: June 30, 2025
A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects.
Journal: American journal of cancer research
Published: March 20, 2025
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.
Journal: Leukemia
Published: January 30, 2025
Regulatory T-cells activated in metastatic draining lymph nodes possibly suppress cancer immunity in cancer tissues of head and neck squamous cell cancer.
Journal: Pathology international
Published: September 28, 2023
A novel mouse model of cutaneous T-cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy.
Journal: Experimental dermatology
Published: December 21, 2021
The dual pocket binding novel tankyrase inhibitor K-476 enhances the efficacy of immune checkpoint inhibitor by attracting CD8+ T cells to tumors.
Journal: American journal of cancer research
Published: October 02, 2020
In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: May 07, 2019
Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 09, 2018
An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.
Journal: American journal of cancer research
Published: July 06, 2018
Last Updated: 09/26/2026